Skip to main content
TipRanks
Go Ultimate75% OFF

PRIM, S.A. (PRM) AI Stock Analysis

0 Followers
ES:PRM

PRIM, S.A.

(BME:PRM)

Select Model
Rating:75Outperform
Price Target:EUR 14.50â–²(16.94% Upside)
Action:upgraded
Date:04/05/26

PRIM's strong financial foundation, highlighted by a debt-free balance sheet and steady revenue growth, is the primary driver of the score. The attractive valuation, with a low P/E and healthy dividend yield, further supports a positive outlook. Technical indicators are neutral, reflecting recent consolidation, but do not outweigh the fundamental strengths. Overall, the stock presents a solid investment with moderate upside potential.

Positive Factors
Debt-free balance sheetBeing effectively unlevered provides durable financial flexibility: lower interest burden, more optionality for capex, dividends or bolt-on M&A, and greater resilience to cyclical shocks. Over the next 2–6 months this supports stable operations and strategic optionality.
Negative Factors
Uneven cash generationIntermittent negative operating and free cash flow in prior years plus a 2025 FCF step-down versus 2024 signal that cash conversion is inconsistent. This reduces the reliability of internally funded growth and increases sensitivity to working-capital swings and capex over the medium term.

PRIM, S.A. (PRM) vs. iShares MSCI Spain ETF (EWP)

-5%0%5%10%15%20%25%30%35%ES:PRM-0.32%EWP+21.91%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 210.17M
Dividend Yield
4.06%
Average Volume (3M)
3,499
Price to Earnings (P/E)
16.3
Beta (1Y)
0.25
Revenue Growth
4.20%
EPS Growth
-10.44%
Country
Spain
Employees
959
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

PRIM, S.A. Business Overview & Revenue Model

Company Description

Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassothera...

How the Company Makes Money

PRIM, S.A. makes money primarily by selling healthcare and medical-technology products to professional and institutional customers (e.g., hospitals, clinics, pharmacies, orthopedic and rehabilitation centers) as well as through retail channels where...

PRIM, S.A. Financial Statement Overview

Summary

PRIM demonstrates consistent revenue growth (8% in 2025) and a robust debt-free balance sheet, with strong cash flow generation. Profitability, while modest (net margin 6.6%), has improved from prior years. The 2023 margin dip appears isolated. Overall financial health is sound.

Income Statement

70Positive

Balance Sheet

85Very Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue250.65M251.82M233.15M216.51M197.25M168.51M
Gross Profit124.50M127.01M112.62M45.30M94.56M83.08M
EBITDA29.07M33.94M26.23M28.05M19.71M30.09M
Net Income13.03M16.68M10.92M12.67M8.39M17.42M
Balance Sheet
Total Assets209.04M196.53M190.28M200.10M184.99M179.85M
Cash, Cash Equivalents and Short-Term Investments25.42M23.03M13.75M13.25M14.94M36.54M
Total Debt14.89M16.28M18.50M25.48M22.07M19.07M
Total Liabilities71.50M58.89M61.34M74.28M65.28M58.38M
Stockholders Equity137.54M137.64M128.93M125.82M119.71M121.47M
Cash Flow
Free Cash Flow23.44M18.14M10.76M-20.09M-7.02M13.87M
Operating Cash Flow36.74M30.46M22.11M-11.33M4.89M26.30M
Investing Cash Flow-11.06M-10.07M-7.59M-3.67M-14.10M-8.70M
Financing Cash Flow-13.43M-11.62M-11.32M10.46M-12.19M-15.09M

PRIM, S.A. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ES:PRM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ES:PRMES:PRM75OutperformEUR 210.17M16.359.47%4.06%4.20%-10.44%
ES:PHMES:PHM67NeutralEUR 1.18B16.7627.64%1.50%32.42%103.06%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ES:ORYES:ORY44NeutralEUR 191.45M-44.66-3.79%――-24.82%
ES:ATRYES:ATRY41NeutralEUR 202.48M-2.08-65.08%―-53.44%-296.14%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%60%ES:PRMES:ORYES:PHMES:ATRYES:LABES:STNADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ES:PRM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ES:PRMPRIM, S.A.12.40-0.19-1.47%
ES:ORYOryzon Genomics2.34-0.65-21.87%
ES:PHMPharma Mar SA66.60-7.89-10.59%
ES:ATRYAtrys Health SA2.67-0.00-0.19%
ES:LABLabiana Health SA4.820.5011.68%
ES:STNASanta Ana Global Enterprises SA15.401.8013.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026